Navigation Links
Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
Date:5/14/2008

SOUTH SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided guidance on its expected monthly cash expenditures following the most recent restructuring undertaken on April 9, 2008. VaxGen expects that its average monthly cash expenditures going forward are unlikely to exceed $1 million, made up of the following categories:

* Costs related to the Company's real estate and facility, estimated at

32% of monthly expenditures.

* Costs related to maintaining public company status, including

professional fees, at approximately 32% of monthly expenditures.

* Costs related to the company's six remaining permanent staff and

temporary support, at approximately 21% of monthly expenditures.

* Interest payments associated with the outstanding convertible debt at

approximately 15% of monthly expenditures.

"With the completion of the most recent reduction in force, we have concluded those significant cost-reduction measures that are under the Company's sole control," said James P. Panek, VaxGen President and CEO. "While we continue to explore every avenue to reduce costs, a further significant reduction will be a function of the resolution of our efforts to sell the manufacturing plant and assign the associated lease. We are in discussions with parties interested in the plant, but cannot at this point provide assurance that a transaction will result."

VaxGen further announced today the filing of its financial results for the quarter ending March 31, 2008 on Form 10-Q with the Securities and Exchange Commission. These results reflect a number of significant impacts consequent to the termination of the proposed merger with Raven biotechnologies as follows:

* Consistent with SFAS 144, "Accounting for the Impairment and Disposal of

Long-Lived Assets" the property and equipment related to VaxGen's
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
2. VaxGen and Raven Terminate Merger Agreement
3. VaxGen Issues Rebuttal to MedCap Letter
4. VaxGen Common Stock Now Quoted on OTC Bulletin Board
5. VaxGen Reports Financial Update
6. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
7. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
10. VaxGen Addresses MPM Claims in Letter to Stockholders
11. VaxGen Files Last Outstanding Periodic Report With SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... 2014 Shire plc (LSE: ... specialty biopharmaceutical company, and ArmaGen, a US privately ... and collaboration agreement for AGT-182, an investigational enzyme ... both the central nervous system (CNS) and somatic ... This collaboration strengthens Shire,s rare disease pipeline of ...
(Date:7/23/2014)... California (PRWEB) July 23, 2014 With the ... in HD resolution for more than 15 minutes, Fastec Imaging ... the world of high speed imaging. “Finally, a high speed ... camera we use in our everyday lives.” proclaims Matt Kearney, ... Fastec has always been to demystify and simplify the traditionally ...
(Date:7/23/2014)... 2014 Astra Nova Training ... consultancy and pharma training services, and the ... , a non-profit integrating the expertise and investments ... a global system for clinical trials, are pleased ... the expertise of industry professionals through improved and ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3
... Mass., Sept. 17 Interleukin Genetics,(Amex: ILI ... Scientific,Officer, Kenneth Kornman, DDS, PhD, will present at ... Alexandria, VA. The conference will,focus on innovative methods ... Among a group of presenters that includes industry ...
... Bio IV NVS Strategic Fund L.P. invests $10 ... Radius Health ("Radius"),announced today that it has ... to,obtain an exclusive worldwide license (except Japan) to ... drug,candidate. BA058 is a proprietary analog of hPTHrP ...
... Medical School researchers have successfully synthesized a DNA-based memory ... step forward in the emerging field of synthetic biology. ... DNA, researchers in the lab of Professor Pamela Silver, ... Systems Biology, not only reconstructed the dynamics of memory, ...
Cached Biology Technology:Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference 2Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference 3Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis 2Scientists synthesize memory in yeast cells 2Scientists synthesize memory in yeast cells 3
(Date:7/23/2014)... Springer will publish the International Journal of Fuzzy ... the Taiwan Fuzzy Systems Association (TFSA). The cooperation will ... the area of fuzzy research., The International Journal ... papers that deal with the theory, design and application ... extension theory systems ranging from hardware to software. Launched ...
(Date:7/23/2014)... , July 23, 2014   MedNet Solutions ... in clinical study management systems, is pleased to ... proven life sciences industry executive with over 25 ... Officer (COO).  Clareece will be responsible for MedNet,s ... operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... the principal bacteria that cause dental caries, has ... time, possibly coinciding with dietary change linked to ... in a study by researchers from the Universitat ... de Genmica para la Biodiversidad (National Laboratory of ... first time, have sequenced genetic material from this ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Ancient genetic material from caries bacterium obtained for the first time 2
... For the first time, researchers at the University of ... to tap into nitrogen found in rocks, boosting the trees, ... the atmosphere. Given that carbon dioxide is the most ... how rapidly the earth will warm in the future, the ...
... CREEK, Calif.Understanding the flow and processing of carbon in ... surface, is central to understanding global climate cycles, with ... below the ocean surface exists a "twilight zone" where ... this, it is known that microbes resident at these ...
... Examining brain damage that occurs when fetuses in the ... Institute have discovered that damage does not occur randomly but ... fatty molecule called LPA, acting through a receptor that transfers ... mice suggests that LPA may also be linked to the ...
Cached Biology News:Bedrock nitrogen may help forests buffer climate change, study finds 2Bedrock nitrogen may help forests buffer climate change, study finds 3Up from the depths: How bacteria capture carbon in the 'twilight zone' 2Discovery suggests way to block fetal brain damage produced by oxygen deprivation 2Discovery suggests way to block fetal brain damage produced by oxygen deprivation 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Normal serum collected from healthy Kunming mice....
Request Info...
Biology Products: